The table below shows Elicio Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$11.64M
-$10.12M
-$12.12M
-$8.14M
-$15.65M
-$12.55M
Capital expenditure
-
-
$0.00
$17.00K
$0.00
$41.00K
Investing cash flow
-
$0.00
$3.00K
-$17.00K
$0.00
-$41.00K
Dividends paid
-
-
-
-
ELTX operating cash flow (10-K history)
Elicio Therapeutics, Inc. reported operating cash flow of -$36.95M for fiscal year 2025. That is up 0.3% from -$37.07M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$22.89M (FY 2020) to -$36.95M. Figures come from the company's audited annual reports as filed with the SEC.